news
EMA initiates ‘rolling review’ of remdesivir, potential COVID-19 treatment
The EMA's human medicines committee has announced it has begun a rolling review of remdesivir for the treatment of COVID-19, to examine its safety and effectiveness.
List view / Grid view
Gilead Sciences
news
FDA grants remdesivir emergency use authorisation to treat COVID-19
The US FDA has given emergency use authorisation to remdesivir for the treatment of patients in hospital with severe COVID-19.
news
Gilead files lawsuit against US federal government over alleged contract breaches
Gilead's complaint alleges five contract breaches by the US Centers for Disease Control and Prevention (CDC) and seeks a declaration of contract breach and damages.
news
Gilead announces primary endpoints met in Phase III remdesivir trial
Gilead has said that topline results for clinical recovery have been demonstrated in a Phase III trial of remdesivir, tested in COVID-19 patients.
news
Two Phase III trials to study remdesivir in COVID-19 patients initiated
Gilead Sciences has announced that two Phase III studies to test the safety and efficacy of remdesivir in COVID-19 patients have begun.
news
New HIV PrEP drug could derail efforts to expand virus prevention coverage
US researchers have stated a newly approved HIV pre-exposure prophylaxis (PrEP) therapy does not have benefits that warrant its price tag and could deter generic competition.
news
Second PrEP preventative HIV treatment approved by FDA
The FDA has announced its approval of Descovy, a PrEP method therapy, to reduce the risk of HIV-1 infection from sex.
news
Two pharma companies collaborate on long-acting HIV therapy
Two pharmaceutical companies have partnered to develop a slow-release drug to treat patients with HIV.
article
A new era for Gilead
As Gilead Sciences enters the rheumatology space, Dr Michael Elliott, Vice President, Medical Affairs Europe, Middle East, Australia & Canada, discusses how Gilead is looking to rapidly build an experienced and committed team to address the unmet medical needs of people living with inflammatory disease.
content_hub
Gilead
17 June 2019 | By
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
news
GS-5734 inhibits a range of emerging coronaviruses
Researchers report on GS-5734, a promising experimental broad-spectrum antiviral drug...
news
Biktarvy approved for the treatment of HIV-1 infection
The FDA has approved Biktarvy a once-daily single-tablet regimen for the treatment of HIV-1 infection...
news
NIH begins large HIV treatment study in pregnant women
Clinical trial will compare three antiretroviral drug regimens...
news
Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability
Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance
news
UK among top performers in access to healthcare, says new report
The Global Access to Healthcare Index measures how healthcare systems across 60 countries are working to solve the most pressing healthcare needs...
